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COMMENTARY
Current challenges of research 
on filamentous fungi in relation to human 
welfare and a sustainable bio-economy:  
a white paper
Vera Meyer1*, Mikael R. Andersen2, Axel A. Brakhage3,4, Gerhard H. Braus5, Mark X. Caddick6, Timothy C. Cairns1,  
Ronald P. de Vries7, Thomas Haarmann8, Kim Hansen9, Christiane Hertz‑Fowler6, Sven Krappmann10, 
Uffe H. Mortensen2, Miguel A. Peñalva11, Arthur F. J. Ram12 and Ritchie M. Head13
Abstract 
The EUROFUNG network is a virtual centre of multidisciplinary expertise in the field of fungal biotechnology. The first 
academic‑industry Think Tank was hosted by EUROFUNG to summarise the state of the art and future challenges 
in fungal biology and biotechnology in the coming decade. Currently, fungal cell factories are important for bulk 
manufacturing of organic acids, proteins, enzymes, secondary metabolites and active pharmaceutical ingredients in 
white and red biotechnology. In contrast, fungal pathogens of humans kill more people than malaria or tuberculo‑
sis. Fungi are significantly impacting on global food security, damaging global crop production, causing disease in 
domesticated animals, and spoiling an estimated 10 % of harvested crops. A number of challenges now need to be 
addressed to improve our strategies to control fungal pathogenicity and to optimise the use of fungi as sources for 
novel compounds and as cell factories for large scale manufacture of bio‑based products. This white paper reports on 
the discussions of the Think Tank meeting and the suggestions made for moving fungal bio(techno)logy forward.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Executive summary
The EUROFUNG network
The EUROFUNG network currently includes 35 aca-
demic members and an industrial platform of 9 European 
biotechnological and pharmaceutical companies, repre-
senting a multidisciplinary virtual centre in the field of 
fungal biotechnology. The mission of EUROFUNG is to 
catalyze new research activities and collaborations across 
disciplines and institutions, to act as a vehicle for com-
munication, and to raise awareness amongst stakeholders 
of priority areas to advance fungal technologies.
The importance of fungi for human welfare and the 
bioeconomy
European companies such as AB Enzymes, BASF, Bayer, 
Chr. Hansen, DSM, DuPont, Novozymes, Puratos and 
Roal Oy are global leaders in using filamentous fungi as 
cell factories in white and red biotechnology. This group 
of microorganisms is often superior to bacterial and yeast 
based production systems, in terms of metabolic ver-
satility, robustness and secretory capacity. Large-scale 
manufacturing processes have been developed for the 
production of organic acids, proteins, enzymes and small 
molecule drugs including antibiotics, statins and steroids. 
Fungal biotechnology thus plays a central role for many 
industries including food and feed, pharma, paper and 
pulp, detergent, textile and bio-fuel. For example, the 
worldwide production of citric acid produced using the 
filamentous fungus Aspergillus niger by far exceeds the 
production of any other organic acid made by microbial 
fermentation. Indeed, the production of plant biomass 
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degrading enzymes by filamentous fungi alone is a €4.7 
billion market, which is expected to double in the next 
10  years. However, filamentous fungi also pose a seri-
ous threat in relation to food supply and safety as they 
reduce worldwide annual crop yields by at least 10  %, 
with the emergence of new hypervirulent isolates and the 
spread of pathogens to new geographic areas continu-
ally reported. Accordingly, the global demand for fungi-
cides to control fungal diseases was a €10 billion market 
in 2014 and is expected to grow continuously in the next 
decade. However, increased agricultural application of 
fungicides in recent years has also led to the development 
of resistance in fungal pathogens that cause diseases in 
the clinic such as pulmonary Aspergillosis. These fungal 
infections threaten the health of more than 1.2 billion 
individuals worldwide and claim the lives of about 1.5–2 
million people every year.
Gaps in knowledge and technologies and strategies 
to address these challenges
To better fight and sustainably exploit filamentous fungi, 
research and development has to significantly advance on 
three different levels:
(i) Science: to overcome our limited understanding of 
fungal biology, the lack of sustainable use and effi-
cient integration of post-genomic data, as well as 
insufficient availability of synthetic biology tools
(ii) Community: to strengthen and connect a rather 
fragmented community consisting of basic 
researchers, medical mycologists, plant patholo-
gists and industrial microbiologists by increased 
funding for multidisciplinary, collaborative and 
translational projects
(iii) Personnel: to provide interdisciplinary training for 
young scientists and technicians that goes beyond 
narrow sub-disciplines
Table 1 summarises ten research opportunities with the 
highest priority identified during the Think Tank meet-
ing and the most pressing resources required to address 
these. Further research opportunities, in addition to 
those highlighted below will be discussed in detail in the 
main text of the white paper including respective recom-
mendations on how to achieve them.
Background
The knowledge-based bio-economy is critical for Euro-
pean growth and development and has been prioritized 
by the EC as a key area that will underpin long term sus-
tainable growth [1]. More specifically, Europe is a world 
leader in the industrial applications of filamentous fungi 
and the underlying science. This group of organisms 
currently has a major commercial impact in product 
areas including food and feed, pulp and paper, textiles, 
detergents, beverages, bio-fuel and chemical production, 
food spoilage and disease. With over 6 million species 
[2], fungi represent a major resource for future sustain-
able applications and processes, but also a potential foe, 
since pathogenic fungi are a serious and growing cause 
of human disease and mortality and a threat to crops and 
food security. Consequently, fundamental and applied 
research dedicated to this broad group of organisms is 
both important and timely.
A Think Tank was organised by the EUROFUNG net-
work on April 28–29, 2016, in Berlin, Germany to dis-
cuss current and future research opportunities and 
future challenges in fungal biology and biotechnology 
over the next 10 years. Industrial and academic contribu-
tors defined the tools, technologies, infrastructures and 
resources required to identify and address challenges, 
and advance fungal biotechnology as a key contributor 
to the European bioeconomy that is essential to sustain-
able growth. Founded in 1995, the EUROFUNG network 
currently includes 35 academic members and an indus-
trial platform of 9 European biotechnological and phar-
maceutical companies (http://mikrobiologie.eurofung.
tu-berlin.de/). This represents a European virtual centre 
of multidisciplinary expertise with globally recognised 
experts and long-term industry/academia collaborations, 
specifically in the field of white biotechnology and fun-
gal biology in general. The EUROFUNG mission is to 
catalyze new research activities and collaborations, to act 
as a vehicle for communication and exchanges between 
academia and industry, and to raise awareness amongst 
key policy makers, funders and the broader stakeholder’s 
community of priority areas to advance fungal technolo-
gies. This white paper summarizes the discussions on 
gaps in knowledge and technologies and the strategies to 
address these challenges.
The importance of filamentous fungi
The global sale volume of white biotechnology prod-
ucts was estimated to be €110 billion in 2008 which is 
expected to increase fourfold to €450 billion by 2020 [3]. 
The proportion of chemicals produced by biotechnol-
ogy will increase significantly within a generation, with 
biotechnology products expected to dominate the spe-
ciality chemicals sector by 2030. European companies 
such as AB Enzymes, BASF, Bayer, Chr. Hansen, DSM, 
DuPont, Novozymes, Puratos and Roal Oy are global 
leaders in using fungi for bulk manufacturing of organic 
acids, proteins, enzymes and secondary metabolites. The 
worldwide production of citric acid produced with the 
filamentous fungus Aspergillus niger is about 1.6 million 
metric tons, a number that far exceeds the production of 
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any other organic acid made by fermentation [4]. It is the 
most widely used organic acid in foods, beverages, phar-
maceuticals and technical applications and the market 
size continues to grow. Itaconic acid produced by Asper-
gillus terreus is a commodity used by the chemical indus-
try for the production of synthetic resins, fibres, plastics, 
rubbers, surfactants, and oil additives, which has resulted 
in an increased demand for this product. Other multi-
functional organic acids of filamentous fungal origin such 
as succinic, fumaric and malic acid are exploited as com-
modities for the manufacture of biodegradable polymers. 
Fungal enzymes are used within large-scale manufactur-
ing processes, including paper and pulp, food and feed, 
beverages, wine, detergents, textiles, and bio-fuel pro-
duction. Large-scale production of key building blocks 
for active pharmaceutical ingredients has also been suc-
cessfully established in filamentous fungi as exemplified 
by Bayer’s steroidal progrestin drospirenone (>€0.54 bil-
lion in the first 9 months of 2015). Indeed, the majority 
of enzymes used worldwide are produced by filamentous 
fungi. In 2015, the global market for industrial enzymes 
was estimated to be worth 3.5 billion euros, with Novo-
zymes and Dupont having a 48 and 20  % share of the 
market respectively [5]. Notably, this industry is engaging 
interest from other agricultural suppliers, including Bayer 
CropScience, BASF, Syngenta/DSM, and Chr. Hansen 
[5]. Several species of Aspergillus as well as other fungi, 
including Trichoderma reesei and Myceliophthora ther-
mophila, are important for industrial enzyme produc-
tion. The metabolic diversity of fungi and the broad range 
of ecological niches they inhabit mean that many species, 
especially the basidiomycetes, have significant potential 
as sources of novel enzymes for future exploitation.
Fungal bioactive compounds ranging from antibiotics 
to statins have saved the lives of millions since the dis-
covery of penicillin by Alexander Fleming in the 1920s. 
These are generally secondary metabolites or their deriv-
atives and their industrial production is and will continue 
to be a major activity. Again there is significant potential 
in the identification and production of novel compounds 
and to re-design and repurpose them by means of syn-
thetic biology. However, antimicrobial resistance of bac-
teria is currently spreading, whereas the number of newly 
discovered antibiotics is declining [6]. The dramatic 
increase in antimicrobial resistance has led the World 
Health Organization to call for urgent and concerted 
action on research and innovation to develop novel tools 
[7] and the G7 health ministers to call for accelerated 
research and production of new antimicrobial agents 
(Declaration of the G7 Health Ministers, Summit 2015).
Fungal pathogens kill more people per year globally 
than malaria or tuberculosis (estimated 1.6–2 million 
Table 1 Summary of the EUROFUNG’s Think Tank
Research opportunities Community resources required
Understanding basic principles underlying fungal growth, development 
and gene expression
Investment in a well‑structured dedicated science base including 
European and international initiatives (e.g. COST actions) to optimise 
knowledge exchange and efficient multidisciplinary activities
Development of publicly available gene deletion and overexpression 
mutant libraries
Sustainable investment in appropriate strain culture collections
Development of high‑throughput technologies for cloning, mining and 
screening of fungal strains
Combined activity between technology developers and experts in fungal 
science to modify technologies according to specific challenges of 
filamentous fungi
Development of genome editing and synthetic biology tools for high‑
throughput manipulation and (re)design of fungal genomes
Dedicated funding for methods and tool development regarding generic 
synthetic parts and easily adaptable molecular components for integra‑
tion into experimental pipelines for filamentous fungi
Development of publicly available, high‑quality manually curated omics 
databases where fungal genomes and omics‑studies can be shared
Continuous and suitable investment in appropriate bioinformatics 
resources, structures and staff training
Development of strains with improved protein expression and secretion 
rates
Development of strains with improved macroscopic morphologies in 
submerged cultures
Development of optimal/minimal genomes lacking unwanted mycotoxin 
genes
Understanding fungal pathogenesis in different hosts and across kingdoms 
including the development of infection models
Dedicated research activities including cross sector forums to investigate 
human, animal and plant pathogens and disease ecology. Direct links 
to clinical and agricultural global science activities and policy makers 
(WHO, FAO, EC)
Selection of appropriate targets for antifungals and establishment of drug 
development strategies
Dedicated funding for screening programmes to identify new modes of 
action against key targets and translation into well‑financed early stage 
development pipelines
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[8]). The main causative agents of human deaths are 
found in the genera Cryptococcus, Candida, and Asper-
gillus, whereby the genus Aspergillus causes between 38 
and 80  % of fungal disease-associated mortality across 
Europe, depending on geographical location [9]. The 
damage caused by fungi to global cereal production 
including rice, wheat and maize is also alarming. More 
than 10 % of the annual harvested crops are estimated to 
be spoiled by fungi [10] and the global demand for fun-
gicides was a €10 billion market in 2014 and expected to 
grow at 5.3 % by 2019 [11]. Finally, there is an important 
and increasing need to detect fungi and their metabolites 
in relation to food safety and security, crop protection, 
domestic environments (i.e. as a cause of sick building 
syndrome), and clinical diagnosis, as recognized through 
recent EU legislation.
Key challenges to exploit and fight filamentous 
fungi
The Think Tank identified several key barriers which limit 
optimum exploitation of filamentous fungi and hamper 
our ability to design new and sustainable antifungal strat-
egies. The barriers fall into three categories:
(i) Science: The limited range of molecular and syn-
thetic biology tools and high-throughput technol-
ogies tailored to filamentous fungi delays research, 
product development and the identification of 
antifungal targets, limits flexibility in engineer-
ing the required combinations of genome modi-
fications and appropriately regulated transgenes. 
Effective integration of the rapidly growing post-
genomic data is limiting systems biology, while 
also hampering metabolic modelling and engineer-
ing approaches. In particular, advanced metabo-
lomic analysis and profiling of fungal organisms is 
not well developed in spite of the obvious poten-
tial for both exploitation and manipulation of their 
diverse metabolism. Overcoming these limita-
tions will facilitate the development of new prod-
ucts and biosynthetic systems. Finally, fungal bio-
tech companies are dependent on poorly defined, 
highly mutagenized, production strains. This 
can be overcome by the rational development of 
strains with optimum genomes, providing defined 
robust hosts for synthetic biology and accelerated 
product development.
(ii) Community: The range of organisms and the 
diversity of potential products associated with fila-
mentous fungi is reflected in a community which 
is inevitably broad but also fragmented. One con-
sequence is the limited number of appropriate EU 
calls or multinational collaborative projects in spite 
of significant funding from national programs. 
Increased European funding would help reduce 
fragmentation and better explore this diversity and 
potential.
(iii) Personnel: The long-term development of fungal 
biotechnology is dependent on recruiting the best 
young scientists and research staff, providing them 
with effective, interdisciplinary training that goes 
beyond narrow sub-disciplines, giving them the 
confidence, enthusiasm and networks to progress 
in their careers.
The participants agreed that the coming decade will offer 
many opportunities and challenges for R&D on filamen-
tous fungi. The exploitation of filamentous fungi will 
contribute significantly to the realisation of a secure, sus-
tainable, bio-based future. To achieve this, the following 
key questions and challenges need to be answered:
1. How do we exploit filamentous fungi in more effi-
cient and sustainable ways in biotechnological, phar-
maceutical and agrochemical industries?
2. What is the best way to develop new antifungals and 
sustainable strategies to fight plant and human path-
ogens?
3. How can synthetic biology contribute to the design 
of optimised fungal genomes?
4. What are the optimal approaches to analyse and pro-
vide access to fungal–omics data to realise their full 
potential?
5. What are fungal model organisms good for?
6. Which technologies need to become developed and 
integrated to better understand fungal growth and 
development?
7. Which training programs are key for the next-gener-
ation of fungal scientists?
Exploitation of filamentous fungi 
by biotechnological, pharmaceutical 
and agrochemical industries
Historically, filamentous fungi were used to produce 
enzyme complexes containing a number of different 
activities necessary for degradation of e.g. plant materials 
like (ligno-)cellulose, starch, pectin, hemicellulose, pro-
tein, and lipids. These enzyme activities are still widely 
produced but the products today are more refined. Tra-
ditional strain improvements were mainly achieved by 
mutagenesis and screening to remove specific unwanted 
activities and for general increase of expression of com-
plex components. The advent of recombinant technolo-
gies enabled tailoring of enzyme complexes by specific 
deletions and overexpression became possible. Devel-
opment of clean production hosts deleted for unwanted 
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extracellular proteins also improved product quality and 
production economy. Further, optimized variants of nat-
ural enzymes have been enabled by protein engineering 
e.g. to improve stability at relevant industrial conditions 
(temperature, pH). Today, the main enzyme activities 
produced in fungi are used in the food industry (alpha-
amylases, glucoamylases, proteases, pectinases, xyla-
nases), the feed industry (phytases, xylanases), the biofuel 
industry (glucoamylases, invertases, (hemi)-cellulases) 
and the detergent industry (lipases, endo-glucanases). 
However, achievable expression levels of similar pro-
teins still varies a lot and some enzymes are very difficult 
to produce in a cost-effective manner, so more versatile 
and higher yielding host strains are needed to extend the 
range of commercial enzymes.
Several decades ago, fungal microorganisms ena-
bled oxidative functionalization of natural steroids (e.g. 
Upjohn’s cortisone process [12]) and currently, they are 
used in the production of steroidal drugs and oxidative 
functionalization of steroidal [13] and non-steroidal 
building blocks. There is a renewed and growing interest 
of pharma industry in using filamentous fungal enzymes, 
particularly for catalysing biooxidations. Since 75  % of 
drugs are metabolised by human p450 cytochromes [14], 
fungal oxygenases are of interest to mimic human liver 
biotransformations. In addition, oxidative functionaliza-
tion of natural products or bioactive leads is an emerg-
ing technology for providing novel chemical entities to 
bioactivity testing. Fungi are a rich source for highly rele-
vant biooxidation catalysts; but know-how about specific 
monooxygenases and their coupled oxidoreductases is 
very limited and precludes further optimization options 
including directed evolution approaches for turnover 
or selectivity fine tuning. However, combining fungal 
monooxygenases with fungal or non-fungal host systems 
for developing a fit-for-purpose biooxidation toolbox 
may allow for production-scale application of enabling 
CH-biooxidation processes overcoming current limita-
tions of recombinant E. coli or yeast based biooxidation 
catalysts. Furthermore, transaminases, imine reductases, 
ketoreductases and lipases are the most relevant enabling 
enzyme classes for pharma R&D applications. Using fila-
mentous fungi for transaminases as well as imine and 
keto reductases would be highly attractive synthetic 
chemists in pharma R&D if benchmarking against cur-
rently available enzymes shows a broadened substrate 
scope or beneficial stability profiles.
Finally, natural products still play a role in pharma R&D 
for identifying novel modes of actions or as early leads. 
Hence, novel natural products (e.g. from the hidden treas-
ures of fungal genomes) should be screened and profiled 
in biological systems with a clear need for new mode-
of-actions (e.g. activity, modulation of tumor immune 
response, inhibitors for chromatin modifying enzymes). 
For cancer indications, novel natural products may be 
interesting either as antibody drug-conjugates payloads or 
if they show unprecedented antiproliferative fingerprints 
(e.g. selective killing of cell lines from specific tumor 
indications). As synthetic access is still the major limita-
tion for using natural products as pharma leads, synthetic 
biology approaches are highly attractive to overcome this 
hurdle. With a capacity to produce several dozens of sec-
ondary metabolites per filamentous fungus and an esti-
mated diversity of 6  million fungal species [2], there are 
potentially millions of novel bioactive compounds await-
ing their discovery. To unlock this treasure chest (often 
referred to as ‘biosynthetic dark matter’), the development 
of new bioinformatics technologies is required that mines 
(meta)genomic data and connect them with metabo-
lomics and phenotypic data [15, 16].
Filamentous fungi as production hosts
Industrially used filamentous fungi are often superior to 
bacterial and yeast based production systems, in terms of 
versatility and secretory capacity, but to date only a small 
fraction of the potential of filamentous fungi has been 
exploited or is even known. The main reasons are: (i) the 
physiology behind secretion is still poorly understood, 
(ii) knowledge on improved protein secretion for one 
protein is not necessarily transferable to other proteins or 
fungal systems, (iii) limitation of productivity due to non-
optimal macroscopic morphologies and (iv) unwanted 
mycotoxin production during fermentation.
The key challenge is to maximise production at mini-
mal cost, to ensure robustness and accelerate the identi-
fication, engineering and development of new products. 
There are seemingly three strategies going forward other 
than just carrying on as we are, gradually optimizing 
existing production systems: (1) rationally design new 
hosts using synthetic biology, (2) specifically introduce 
beneficial changes identified in established production 
strains and (3) edit out problematic components of fun-
gal genomes, e.g. mycotoxin encoding genes, develop-
mental genes or unwanted proteases. The participants 
agreed that the following developments are of general 
importance for filamentous fungal cell factories:
  • high-throughput technologies for submerged, surface 
growth and co-cultivations
  • development of production strains with regulated 
developmental stages to optimize growth in indus-
trial conditions
  • high-throughput technologies for cloning, mining, 
expression and screening mutants
  • high-throughput technologies for strain construc-
tions
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  • annotation tools for in silico selection of promising 
enzymes and therapeutic targets from genomics data
  • robust computational tools for protein engineering 
(e.g. using machine learning) to fit enzymes better to 
industrial applications
  • miniaturization of cultivation using microtiter plates 
and optimization of microbioreactors
  • development of single-cell analytic tools to study the 
stochastic nature of gene expression and protein syn-
thesis
  • development of production strains with no or 
reduced harmful secondary metabolites production 
including mycotoxins
  • development of production strains that detoxify 
mycotoxin-contaminated raw materials
  • better process designs and process controls for 
improved production
Fundamental questions regarding fungal exploitation 
remain a key challenge
Although there is such a long track record in exploiting 
filamentous fungi as cell factories, our current knowledge 
and understanding of fundamental cellular and develop-
mental processes is severely limited, with many key ques-
tions unanswered. Why are many filamentous fungi not 
able to grow in submerged culture? What are the trig-
gers and signals perceived by fungi when they grow on 
surfaces or in liquid media? Why are some isolates good 
producers on solids but not liquids? How can surface 
production be reverse engineered into liquid growth? 
Why and how does morphology adapts to different sub-
strates and environmental conditions? What defines 
optimal gene structure for expression? Paradoxically, suc-
cessful protein and process engineering has resulted in 
many more ‘black boxes’. Protein improvements are non-
generic and improvements for protein A production are 
not necessarily transferable to protein B or C.
Crucially, the basis of many of the changes underlying 
strain improvement are either undefined or not in the 
public domain. Insights into the genomic evolution of 
production strains which underwent decades of rational 
and non-rational strain improvement programs have, due 
to commercial confidentiality, not been made available 
to academia. Hence, industry has become repositories 
of key knowledge, which has the potential to transform 
our fundamental understanding of fungal metabolism, 
growth and development and that could underpin the use 
of synthetic biology to engineer robust strains and speed 
product development. Exploring mechanisms and collab-
orations to realize this potential will be challenging but 
should represent a priority for the whole community.
Finally, a number of fungi also establish symbiotic rela-
tions with plants forming mycorrhizal structures with 
their hosts. These mutualistic relationships are not only 
fundamental for the cycling of carbon and nitrogen in the 
environment, but also contributes to protect the plant 
hosts against pathogens [17, 18].
The urgent need to fight human‑ 
and phyto‑pathogenic fungi
Ensuring global food security represents one of the great-
est challenges facing humanity in the 21st century. The 
pressures on food production are immediate, but by 2050 
the world will need to increase agricultural production 
by at least 30 % in order to feed its anticipated popula-
tion of 9 billion [19]. A multitude of fungal pathogens 
cause diverse diseases like rusts, smuts, blasts, blotches 
and mildews of staple crops (Table  2), which ultimately 
destroy enough food annually to feed 600 million people, 
approximately 8.5 % of the total population [20]. Fungal 
disease outbreaks also threaten species that indirectly 
maintain crop health, such as the ascomycete Pseud-
ogymnoascus destructans, which causes catastrophic 
epidemics of bats and a subsequent increase in crop-
destroying insects [21]. With regards to climate change, 
trees that are lost or damaged by fungi fail to absorb 230–
580 megatonnes of atmospheric CO2 [20].
Worryingly, the battle lines between fungal pathogens 
and plants are constantly expanding, with the emergence 
of new hypervirulent isolates and the spread of patho-
gens to new geographic areas. As just one example, the 
devastating wheat blast disease caused by Magnaporthe 
oryzae was recently reported in Bangladesh [22]. This 
agricultural emergency is the first case of this disease 
in Asia and has serious implications for wheat produc-
tion throughout the continent. Pathogen geographical 
expansion is likely facilitated by global warming [23], 
and of extreme concern is emergence of multi fungicide 
resistant crop-destroying fungi. Given the serious and 
expanding threats fungi pose to crop and plant health, 
the EUROFUNG consortium advocates that improved 
Table 2 Top 10 fungal pathogens of plants [24]
Rank Fungal pathogen Affected plant(s) Name
1 Pyricularia oryzae Rice and wheat Rice blast
2 Botrytis cinerea >200 Grey mould
3 Puccinia spp. Wheat Rust
4 Fusarium graminearum All cereals Head blight
5 Fusarium oxysporum Multiple Vascular wilt
6 Blumeria graminis Grasses Powdery mildew
7 Zymoseptoria tritici Wheat Septoria blotch
8 Colletotrichum spp. All crops Spots and blights
9 Ustilago maydis Corn Corn smut
10 Melampsora lini Flax Flax rust
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pathogen biosecurity protocols, new fungicides, and dis-
ease resistant plants are urgent scientific and political 
goals.
With regards to infectious diseases of humans, it is 
likely that agricultural application of fungicides has also 
led to the development of resistance in fungal patho-
gens that cause diseases in the clinic, such as the major 
pulmonary pathogen Aspergillus fumigatus [25]. Affect-
ing more than 1.2 billion individuals worldwide and kill-
ing about 1.5–2 million of them, fungal pathogens pose 
a serious global threat [8]. The main causative agents of 
human deaths after opportunistic fungal infections are 
found in the genera Cryptococcus, Candida, and Asper-
gillus (Table 3, from [26]), whereby the latter is linked to 
30–95 % of fungal disease-associated mortality. Even with 
treatment, mortality of invasive aspergillosis remains 
high and increases to 90  % in cases with drug resistant 
isolates [27]. Besides opportunistic infections caused 
by fungal pathogens that mainly affect immuno-com-
promised patients, primary pathogenic fungi can cause 
severe diseases but are mainly restricted to endemic 
areas [26]. It is the steadily increasing group of immuno-
suppressed patients at risk for fungal infections, resulting 
in severe complications in treating the underlying dis-
ease condition. This is not only associated with signifi-
cant mortality rates but also increasing costs of treatment 
[28]. Given that disease is the outcome of a complex 
pathogen-host interplay, understanding the mechanisms 
of both immunity as well as of fungal virulence is key in 
developing innovative therapeutic strategies.
The fungicide and antifungal pipeline is running dry
Fungicides are a critical weapon in the arsenal to pro-
tect crop yields. There are 12 fungicide mode of actions, 
including the inhibition of nucleotide synthesis, respira-
tion, and signal transduction, among others [29]. These 
can be further divided into target sites for which chemical 
groups are active. The most common modes of action are 
targeted by compounds that inhibit respiration or sterol 
biosynthesis (23  % and 22  % of compounds respectively 
[29]). Molecules with new modes of action are urgently 
required due to widespread pathogen resistance to many 
fungicides. For example, the wheat pathogen Zymosep-
toria tritici has growing resistance to demethylation 
inhibitors [30], and recent reports have identified highly 
resistant isolates to the other main control fungicides, 
succinate dehydrogenase inhibitors [31]. Worryingly, 
the number of new active ingredients introduced and in 
development worldwide to combat Z. tritici has fallen 
over the last 30 years [30]. There are similar limitations for 
the fungicide discovery pipeline for all pathogens of major 
crops [29]. The participants unanimously agreed that the 
development of the next generation of so called ‘smart’ 
fungicides is an urgent priority: highly active, broad spec-
trum, low dose, environmentally safe compounds.
For human-pathogenic fungi, a clear lack of novel tar-
gets for antifungal substances is evident too [8]. Cur-
rently approved drugs interfere with the fungal plasma 
membrane, ergosterol biosynthesis, cell wall biosynthe-
sis, or nuclear function as main modes of action. Novel 
compounds that may act over a broad spectrum of spe-
cies are not in sight, which is alarming given the emer-
gence of resistance against some of the most established 
therapeutics. All this is exacerbated due to a chronic lack 
of investment in the antifungal pipeline accompanied by 
challenges in developing such substances when dealing 
with a eukaryotic pathogen.
A roadmap towards new antifungal strategies
Advances in fundamental science, and the emergence of 
fungal omics datasets, have arguably not been harnessed 
by organizations that coordinate global plant biosecu-
rity. There are currently nine inter-governmental plant 
protection organizations, including the European and 
Mediterranean Plant Protection Organization (EPPO). 
These organizations propose protocols for regional phy-
tosanitary measures and run databases for disease recog-
nition, among many other roles. A key theme identified 
by the EUROFUNG consortium was the rapid expansion 
of fungal omics data, and their curation in publicly avail-
able online compendia. These advances have been largely 
ignored in the design and implementation of biosecurity 
protocols, where risk assessments are based on lists of 
known, well characterized fungal pathogens of plants. 
As noted by others, such taxon based approaches ignore 
threats from the many undescribed fungal pathogens, 
do not adequately consider emergence of hyper virulent 
lineages, and are vulnerable to threat mismanagement 
due to highly complex definitions of fungal species [32]. 
Consequently, advances in fungal omics technology and 
databases, most obviously comparative genomics, will 
enable biosecurity protocols to be implemented based 
on systems level biology. Integration of omics compendia 
with existing biosecurity alert databases (e.g. the EPPO 
Global Database, https://gd.eppo.int/) might be one 
Table 3 Most common diseases caused by  fungal patho‑
gens infecting immunosuppressed individuals [26]
Disease Cases/year Mortality 
rates (%)
Aspergillosis >200,000 30–95
Candidiasis >400,000 46–75
Cryptococcosis >1,000,000 20–70
Mucormycosis >10,000 30–90
Pneumocystis pneumonia >400,000 20–80
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way of addressing current shortcomings in biosecurity 
measures.
With regards to development of smart fungicides, 
improved fundamental understanding of pathogen biol-
ogy, at individual gene, protein and systems levels, will 
enable the next generation of compounds to be delivered. 
Encouragingly, there have been many recent advances 
in genetic, molecular and cellular tools that enable the 
multifaceted infection phenotype to be dissected in 
unparalleled detail [33]. These include robotic screening 
and automated analysis protocols, improved virulence 
assays, mutant isolates with elevated rates of homologous 
recombination for efficient targeting of DNA cassettes 
in recipient genomes, heterologous expression systems, 
recyclable markers, and, most recently, CRISPR/Cas9 
genome editing (see below). These tools and techniques 
have identified new potential pathogen targets, based 
on essentiality for disease and other promising criteria 
for rational chemical inhibition. These might include, 
for example, identification of putative targets in the cell 
wall, a fungal specific structure which obviates the need 
for compound transition across the cell membrane. 
Alternatively, rational targets include processes that are 
prerequisites for disease initiation, when pathogen abun-
dance is low and plant damage yet to occur. It is therefore 
important to prioritize methodological initiatives that 
develop tools and resources for the diverse range of crop 
pathogens (Table 1). Most notably, these should include 
CRISPR/Cas9 genome editing, a technique that offers 
unparalleled potential for accurate, versatile and high 
throughput manipulations of fungal genomes [34, 35]. 
Concomitantly, the EUROFUNG consortium advocates 
the development of publicly available pathogen deletion 
or over-expression libraries, which avoids laborious clon-
ing for research groups, and enables functional genomic 
analyses of hundreds or thousands of genes in paral-
lel [36]. Although expanding the repertoire of rational 
pathogen targets is a vital component of the fungicide 
discovery pipeline, determining which of these are able to 
be inhibited by a compound—finding so called ‘drugable’ 
targets—is a highly challenging. Obviously, compound 
libraries are a critical resource for overcoming this bot-
tleneck, yet access to large, biologically active, structur-
ally diverse compound libraries is limited for research 
groups outside industry. Indeed, it is clear that the capa-
bilities of industry to conduct and interpret chemical 
screens are far more advanced that most non-industrial 
counterparts; Syngenta, for example, are able to screen 
300,000 compounds per year [30]. Moreover, industry 
has the necessary expertise and infrastructure to develop 
new chemical leads and ultimately bring novel fungi-
cides to market. Consequently, private–public partner-
ships hold huge potential for translating new pathogen 
targets or chemical leads into the next generation of 
smart fungicides.
For developing novel agents acting against human-
pathogenic fungi, several deficiencies in research are 
evident, among them the lack of comprehensive mutant 
libraries and shortcomings in infections models. In 
modeling the host-pathogen interactions that result in 
disease, systems biology has to be seen as state-of-the-
art approach. Within this field, network analyses can be 
applied to predict common points of attack that may be 
exploited for future antifungal therapies against a wide 
range of human-pathogenic fungi. Such network mod-
eling approaches can comprise regulatory circuits or 
fundamental aspects of fungal physiology, like primary 
metabolism [37]. A crucial prerequisite for addressing 
putative virulence determinants in fungal pathogens is 
an advanced molecular biology that allows precise and 
defined manipulation of the fungal genome of interest 
and tight conditional gene expression. In this respect, 
several limitations and differences exist among the range 
of human-pathogenic fungi, hampering the identifica-
tion of general principles of fungal virulence. To address 
this requires the implementation of smart tools for fun-
gal molecular biology accompanied by the generation 
of genome-wide mutant strain libraries. This will allow 
the development of efficient screens for antifungal tar-
gets such as essential genes. These may then be analyzed 
with respect to their drugability to provide perspectives 
for novel and innovative antifungals with new modes 
of action. The fact that most antifungals are fungistatic 
rather than fungicidal requires special attention with 
respect to the emergence of resistance and secondary 
effects. Furthermore, the usual timelines for develop-
ment and approval, which is about 10 to 15 years, under-
lines the need for urgent action and acceleration of the 
processes that define the antifungal pipeline. A further 
perspective lies in common principles of fungal viru-
lence that may be executed by phyto- as well as human-
pathogenic fungi and that have not been analysed on a 
comprehensive scale so far: understanding fungal patho-
genesis in different hosts across kingdoms holds the 
promise of extracting fundamental modes of action that 
may be exploited for universal targets, thereby narrowing 
the scope of candidates when screening for novel anti-
fungal compounds [38].
Synthetic biology as a new technology for basic 
research and cell factories
Most strain development programs for industrially 
exploited filamentous fungi started by using classical 
mutagenesis and selection. This has been very success-
ful in generating highly productive strains but has also 
led to strains that are often impaired in general fitness. 
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This is mainly due to unfavorable mutations occurring 
and accumulating during consecutive rounds of classical 
mutagenesis. In addition, under certain conditions fungal 
strains are able to produce a huge number of secondary 
metabolites including mycotoxins and initiate develop-
mental programs that interfere with industrial processes. 
To circumvent these pitfalls, the EUROFUNG consor-
tium advocates a more targeted strain development 
approach eventually culminating in the design of an opti-
mal fungal genome. Here synthetic biology tools in gen-
eral and more specifically genome editing via CRISPR/
Cas9 comes into play. The optimal fungal genome should 
contain all genes necessary for fitness, high productiv-
ity, and robustness in industrial conditions and has been 
gradually down-sized by eliminating dispensable meta-
bolic pathways or secondary metabolite gene clusters.
Genome editing and the CRISPR/Cas9 revolution
Over the past decade, the ku70/ku80 tool box has made 
it faster and easier to study gene function in filamentous 
fungi. Despite this major improvement of gene targeting 
efficiency, only a full gene knock-out library for Neuros-
pora crassa has been completed [39], and a second col-
lection of whole genome gene knock-out mutants in A. 
fumigatus is on its way [40]. For A. nidulans a near com-
plete set of deletion constructs was produced for each 
gene and is available for the community [41]. Despite the 
usefulness of high efficiently gene targeting by inhibit-
ing non-homologous end joining, and robotizing the 
methods for constructing gene replacements cassettes, 
mutant generation and verification remains laborious. In 
addition, no genome-wide libraries exist for systematic 
GFP-tagging, gene overexpression or tunable expression 
of essential genes. The use of CRISPR/Cas9 systems for 
gene editing and loss of function mutants has proven to 
be a powerful tool for loss-of-function analysis [35, 42, 
43]. Generating increase knowledge of gene function in 
filamentous fungi is now highly desirable to allow the 
development of robust cell factories and identification of 
targets to fight human and plant pathogenic fungi.
With the simultaneous expression of multiple guide 
RNAs, the CRISPR/Cas9 system allows multiplexed 
genome editing, offering the possibility to quickly cre-
ate multiple gene knock outs in a single experiment. 
The multiplex CRISPR/Cas9 technology, in combination 
with marker free disruption of genes, make approaches 
to optimise cell factories feasible, for example in the 
production of secondary metabolites by removing all 
unwanted secondary metabolite gene clusters. Likewise, 
optimal cell factories for production of (recombinant) 
proteins will benefit from the simultaneous deletion of 
genes encoding extracellular proteases. However, parallel 
analysis of large numbers of mutants and the risk of cross 
contamination due to spore dispersal still remain a chal-
lenge and limit the speed of high-throughput screening 
for filamentous fungi. Hence, better methodologies need 
to be developed to culture filamentous fungi in microtiter 
plates with reproducible submerged growth characteris-
tics and no or reduced sporulation.
CRISPR/Cas9 is not limited to the construction of gene 
disruptants: it can also be used for sophisticated genome 
modifications to create GFP-gene fusions to study pro-
tein localizations though exogenously supplied ‘donor 
templates’ that can be targeted to the gene of interested 
via a properly designed sgRNA [42]. Similarly, CRISPR/
Cas9 allows the introduction of specific mutations, stop 
codons or alterations in potential transcription factor 
binding sites to study protein function or DNA–protein 
interactions. Finally, the CRISPR/Cas9 technology has 
great potential to study the function of essential genes 
and to study genes by overexpression by swapping endog-
enous promoters for tight, tunable and metabolism-inde-
pendent promoter such as the Tet-On/Tet-Off system 
[44]. Deactivated Cas9 (dCas9) lacking endonuclease 
activity while maintaining an ability to specifically bind to 
DNA sequences can act as activator or repressor of target 
genes. This approach has been successfully used in E. coli 
[45, 46] and eukaryotes [47] and has great potential to 
prevent or activate gene expression in filamentous fungi.
Synthetic chromosomes and genomes as future drivers 
of basic and applied sciences
A synthetic variant of the bacterium Mycoplasma 
mycoides has recently been constructed demonstrat-
ing life functions, including self-replication [48]. Similar 
efforts are ongoing for the yeast Saccharomyces cerevi-
siae [49]. These landmark advances offer the possibility 
of creating organisms that are tailored to support spe-
cific production processes or to answer specific research 
questions. As DNA synthesis and engineering tools are 
now ready to construct small genomes, it is intrigu-
ing to speculate that similar constructions will be pos-
sible in filamentous fungi in the near future. As for M. 
mycoides and S. cerevisiae [50, 51], one of the first goals 
is to define a minimal genome for filamentous fungi. 
Bioinformatic analyses of the many fungal genomes that 
are currently accumulating are likely to identify large 
numbers of dispensable genes that can be eliminated 
using Cas9 multiplexing gene deletion strategies. Such a 
chassis can be used as the clean background for the pro-
duction of enzymes and secondary metabolites minimiz-
ing the risk of co-production of undesirable mycotoxins 
or undesired cross-chemistry that complicates pathway 
analysis and reduces yields. In addition, a fungus with a 
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minimal genome will be an excellent host for analyzing 
multiple areas from aspects of the primary metabolism 
to development. A subsequent step could be de novo 
chromosome design implementing large expression 
platforms for multi-gene pathways for the production of 
metabolites requiring large gene clusters. Such platforms 
should be compatible with modular cloning strategies 
that efficiently combine elements such as promoters, ter-
minators, selectable markers, and sequences that target 
fragments to defined expression sites, facilitating effi-
cient strain construction. Insertion of large gene clusters 
may be performed by the combined use of intra-cellular 
homologous recombination to fuse PCR fragments with 
relevant genes and for insertion into the genome in a 
process that can likely be stimulated by Cas9 as has been 
shown for S. cerevisiae [52]. Potentially, platforms could 
be constructed that allow for insertion of many identical 
gene copies in a stable and defined manner to increase 
production of specific proteins. In the yeast Sc2.0 pro-
ject, symmetrical loxP sites are inserted between non-
essential genes and recombination between the sites can 
be induced by expression of the Cre recombinase [53]. 
Implementing a similar system in filamentous fungi may 
have a wide impact, considering that many fungi are dif-
ficult to cross as a sexual cycle does not exist, is elaborate 
and difficult to perform, or remains to be discovered. 
Uncovering the sexual cycle, or restoring it in industrial 
strains where is has been lost during strain development, 
has significant potential for strain development (e.g. 
[54]). Additionally, enhanced and defined recombina-
tion in a parasexual cycle based procedure could set the 
stage for efficient strain development. For example, hap-
loid strains that have been selected after random chemi-
cal or radiation induced mutagenesis could be fused to 
form diploids. The genomes could then be scrambled by 
synthetic biology based recombination followed by hap-
loidization to produce strains with new gene combina-
tions that may further benefit production. This strategy 
may even be used for quantitative loci analyses to pin-
point genes that are relevant for desirable phenotypes 
[55].
What are the optimal approaches to deposit 
and analyze fungal–omics data and to extract 
meaningful biological information from it?
Systems biology approaches have become integrated 
in nearly every research area involving fungi and one 
can hardly find an academic research project that does 
not leverage high-throughput technologies to analyses 
genomes, transcriptomes or proteomes. However, the 
EUROFUNG consortium foresees that this development 
also presents the wider research community with a num-
ber of key challenges.
Quality of fungal genome datasets
Quality of fungal genome datasets: The participants 
agreed that the quality of fungal genome sequence data 
is highly variable, thus limiting the reliability of genome 
comparisons. While the limitation in quality of the early 
genome sequences was mainly due to the sequencing 
technology, more recent genome sequences—while hav-
ing a higher quality and better assembly—suffer from 
poor annotation and propagation of errors due to auto-
mated annotation. Up to around 2010, a fungal genome 
sequence could be published in high impact journals, 
and therefore consortia were formed to improve the 
automated gene calling and annotation by manual cura-
tion and verification of genes [56, 57]. Nowadays, with 
the exponential increase in genome sequencing, very few 
genomes make it past the initial draft annotation and 
while these are better in terms of coverage and assembly, 
they generally lack well-supported and verified annota-
tions. The use of automated annotation is dependent on 
existing annotated genomes as a reference, consequently 
any errors are likely to be propagated; an issue com-
pounded by limited resources for manual annotation 
efforts. 
A key determinant of the utility of a genome sequences 
is the accuracy of gene calling. This is more complex in 
filamentous fungi than many organisms due to high 
numbers of introns and the prevalence of antisense tran-
scripts. RNAseq has a major role in refining gene mod-
els but many studies are technically limited, for example 
employing strand-specific analysis is essential in under-
standing splicing frequency and antisense identity and 
prevalence and a wide range of growth conditions are 
required to observe a large proportion of transcripts. A 
fundamental aspect is the ability to define precisely the 
5′ and 3′ ends of transcripts, as this helps identifying 
features such as the promoters, terminators and cod-
ing sequences. If miss-called, downstream experimen-
tal analysis, such as the production of mutant libraries 
for altered expression or protein tagging will be severely 
handicapped. Therefore, there is a need for the use of 
more refined techniques to define transcripts and genes, 
such as targeted analysis of both the 5′ and 3′ ends [58] as 
well as full-length transcript sequencing using technolo-
gies such as PacBio [59].
Accessibility to fungal datasets
Currently, fungal genome sequences are hosted at differ-
ent resources, such as JGI’s Mycocosm, AspGD, FungiDB, 
NCBI, and several others [60]. The groups generating 
the data often use different algorithms for assembly and 
annotation which can complicate the comparison of 
genomes that are not in the same resource. Furthermore, 
even though some genomes are included in all these 
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resources, it is not always the same version of the annota-
tion or sequence that is used and the tools to access them 
often use different default settings, which means that the 
‘same’ search applied to the ‘same’ genome at a different 
resource can provide different results. This severely com-
promises the quality of fungal research and the reliability 
of the data generated, in particular by third parties. It is 
critical for the future of genomics-driven fungal research 
that anyone can have full access to reliable genomic infor-
mation, and every effort should be made to make it so.
Comparability of fungal datasets
For most fungal species only a single genome sequence is 
available. The choice of strain used for genome sequenc-
ing is often arbitrary: availability in the lab, typical model 
strain, type strain, etc. Even for type strains, this is in no 
way a guarantee that the selected strain is the most rep-
resentative for a given species. For instance, a strain that 
has been in the lab for many generations may have lost 
some of its ‘natural’ characteristics such as virulence. The 
first isolate to be discovered in a species is often made 
the type strain, but may not be representative of the spe-
cies complex. Therefore, conclusions about differences 
between species based on the genome of a single strain 
may not reflect the actual diversity of these species. Con-
sequently, care should be taken when analysing such data.
Unfortunately, omics data resulting from these studies 
are rarely used in follow-up or comparative studies. There 
are two main reasons for this: First, omics data is typically 
deposited in raw formats in databases, which makes it de 
facto unusable for a large proportion of researchers who 
do not have the required bioinformatics skill set. Second, 
there is substantial variation in experimental conditions 
between datasets, which makes comparability difficult. 
While it will be hard to prevent this, it would be desir-
able for the research community to define ways to enable 
more comparative studies of datasets from different labs. 
Further challenges exist for fungal metabolomics, such as 
the absence of good fungal metabolite reference libraries, 
variation of methodology (e.g. different mass spectrom-
etry platforms) and the absence of a good public reposi-
tory of these data. As mentioned before, metabolomics 
has the potential to initiate new and improve existing 
applications but significant time and financial invest-
ments are needed to make this a reality.
Maintenance and sustainable use of fungal datasets
Overarching all of the issues above is the availability and 
use of high-quality manually curated omics databases 
where genomes and other omics-studies can be shared. 
The participants of the meeting agreed that the effort 
required to maintain such resources, where literature and 
data is extensively curated by experts, is substantial but 
justified considering the added value which would come 
from such efforts. More accessible data, high-quality 
annotation, and a systematic framework to link research 
publications with the fungal genomes would significantly 
accelerate fungal research. Importantly, linking research 
findings to the respective genomes through public data-
bases inevitably increases the impact of individual stud-
ies, the genomes and associated datasets. As the mass 
of fungal literature currently doubles every 7–8  years, 
sifting through the respective data and publications 
will only become more challenging in the future. Most 
importantly, European researchers, funding agencies and 
policymakers should seriously consider the way fungal 
genomics data should be organized and the European 
role in this. Currently, infrastructure for fungal genom-
ics is strongly dependent on US and UK initiatives and 
very few European funded initiatives contribute to a 
well-organized infrastructure to host and analyze fungal 
genomes, transcriptomes and proteomes. Should access 
to the US infrastructures become limited for non-US 
scientists or US investment in databases significantly 
reduced, as recently seen for AspGD and the Broad 
Institute resources, this will create serious problems for 
European fungal research. Omics data is very cost effec-
tive but its utility is largely dependent on making the data 
accessible and usable by the wider research community. 
Without suitable investment in appropriate resources 
and structures much of the potential value of such data 
is lost and the investment in the original studies squan-
dered. Most alarmingly, the National Human Genome 
Research Institute (NHGRI), which funds several of the 
model organisms’ databases (yeast, worm, fly, zebrafish, 
and mouse) and the Gene Ontology consortium, has 
recently announced there will be decreased funding by 
30 % over the next few years for these resources [61, 62].
What are fungal model organisms good for?
Both the useful facets of filamentous fungi and in some 
cases their devastating biological activities are intimately 
rooted within the ‘filamentous mode of life’. The ‘refer-
ence system’ for filamentous fungi has been, traditionally, 
the budding yeast S. cerevisiae, due to its phylogenetic 
relatedness to filamentous fungal ascomycetes and to 
the wealth of knowledge colleagues working with this 
unicellular ascomycete have amassed. However, it must 
be acknowledged that the budding yeast is, for many 
aspects, too specialized and limited to play the same 
lighthouse role in the future. To put just a few examples, 
the genomic duplication that took place in the Saccha-
romycotina line [63] resulted in a notable degree of gene 
redundancy, which often complicates functional analyses. 
Moreover, even with the genome duplication notwith-
standing, the budding yeast genome codes for half the 
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number of genes of filamentous ascomycetes. As many 
fungal genes do not have a yeast orthologue a large pro-
portion remain ‘uncharacterized’. Accurate annotation 
of filamentous fungal genomes had to overcome the dif-
ficulties imposed by the abundant introns, a problem that 
was not encountered by our budding yeast colleagues. 
Budding yeast and its ancestors have lost RNA interfer-
ence mediated transposon resistance and exhibit a high 
internal reverse transcriptase activity combined with 
an efficient homologous recombination system which is 
presumed to account for the unusually low number of 
introns [64]. The S. cerevisiae network of metabolic path-
ways, streamlined for growth on ‘compositionally spe-
cialized’ substrates, is very limited in the case of primary 
metabolism, and in the case of secondary metabolism 
essentially absent. This makes the ‘model’ yeast a poor 
model for studies aimed at understanding and exploit-
ing many biotechnologically useful features of fungal 
metabolism, including the often neglected cell biology of 
secondary metabolite production. In terms of basic cell 
organization, laboratory strains of budding yeast have 
usually lost the natural ability to grow as filaments, which 
is restricted to pseudohyphal growth [65]. Remarkably, 
budding yeast uses microtubules (MT) solely for mitosis 
and nuclear positioning, whereas the organization of fila-
mentous fungal hyphae largely relies on MT dependent 
transport, such that MT-dependent processes strongly 
affect growth, including invasiveness and pathogenicity, 
as well as secondary metabolite and enzyme production. 
From the organismal point of view, filamentous fungi 
undergo developmental processes, shaping the sexual 
and asexual reproductive structures that have no paral-
lel in the budding yeast. As development appears to be 
intimately connected to secondary metabolism [66] and, 
undoubtedly, to fungal pathogenicity - there is no infec-
tion without efficient propagation. For these and many 
other reasons we need to turn our gaze to organisms 
other than S. cerevisiae. Thus it seems clear that future 
progress will be less yeast-centric, emphasizing the need 
for better fungal experimental ‘models’.
The term ‘model/s’ can be misleading, and requires 
a shift in focus towards the more appropriate term 
‘reference/s’ organism/s, more suited to match specific 
problems. For example, it is hardly disputable that the 
‘reference’ species to understand conidiophore devel-
opment, or to unveil fundamental differences between 
MT-mediated intracellular traffic between filamentous 
ascomycetes and the budding yeast is A. nidulans [67], 
but arguably no sensible colleague would try to under-
stand citric acid production without metabolic mod-
els based on A. niger as ‘reference’, or will work on the 
Spitzenkörper without turning his/her eyes to studies 
with N. crassa [68]. This discussion on ‘references’ boils 
down to a reconsideration of the ‘basic unit of research’, 
which arguably should be ‘the problem’ (i.e. ‘germina-
tion’, ‘dimorphism’, ‘sensing’) rather than ‘the organism’. 
Indeed the mechanistic details may be slightly differ-
ent in the different instances (i.e. organisms), and such 
a ‘problem-centric’ approach might be helpful to sort 
out the common denominator (the actual basic-thus 
common-gear). This problem-focused approach might 
enable a more holistic understanding of the fungal 
kingdom.
A frequently encountered problem common to all 
species is the need for better tools for gene inactiva-
tion. Studies with knockout alleles, albeit useful to take a 
quick glance at the function of a given gene, is restricted 
to those genes that are not essential or nearly so (a score 
of knockout alleles debilitate growth to an extent that 
although not strictly leading to lethality preclude any 
further study). A way around the ‘essentiality problem’ 
is the use of tight conditional expression systems [44]. 
Null mutations only provide clear mechanistic insights, 
when e.g. a gene encoded enzyme activity can be meas-
ured or a linear signal transduction pathway is inter-
rupted. However, the mechanistic conclusions are highly 
limited, when phenotypic consequences reflect ‘collateral 
damage’ rather than the absence of the specific function 
of the gene in question. Here, conditional expression sys-
tems are limited by the fact that the turnover of the pro-
tein whose function is inactivated might be unbearably 
long. Thus, there is an urgent need of tools that permit 
the acute inactivation of gene expression. Thus far, such 
weaponry is reduced to temperature-sensitive alleles, 
which ideally inactivate a protein only in cells incubated 
at the ‘restrictive’, but not at the ‘permissive’, temperature, 
usually by promoting protein misfolding/degradation. 
One problem is that these mutations are available largely 
in those organisms that have been traditionally used for 
classical genetic studies, such as N. crassa, A. nidulans 
and Ustilago maydis, but scarce in industrial or clinical 
species. A second is that temperature-sensitive growth 
does not necessarily reflect the complete inactivation of 
an otherwise essential protein at the restrictive tempera-
ture, but in many cases, a stronger requirement for the 
function of the said protein at elevated (stress-causing) 
temperatures, under which a hypomorphic allele will 
not sustain growth. A third is that if the restrictive tem-
perature for a given allele is too high, its usefulness may 
be limited (for example, it may not be suited for in vivo 
microscopy studies, as the optics cannot be ‘heated’ 
beyond 38 °C). Thus there is a very strong need for bet-
ter genetic switches, such as those based on conditional 
degrons inspired in tools developed for the budding 
yeast [69]. Doubtless, the development of these and other 
tools for conditional gene inactivation will be strongly 
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influenced by the recent development of CRISPR/Cas9 
technologies for filamentous fungi as discussed above. 
Note that CRISPR will not only deeply impact experi-
mentation but legal regulations as well [70].
Lastly, there is a strong need for ‘reference’ organisms 
to be amenable to classical genetics, the feature that in 
the first place made filamentous fungi useful experi-
mental systems. For example, the identification of causa-
tive mutations by genomic mapping is largely facilitated 
by previously knowing the localization of the mutation 
in a genetic map [71, 72]. Also transformation is muta-
genic and it should be a rule of thumb to demonstrate 
that the phenotype of a recombinant allele segregates in 
a Mendelian fashion, as otherwise the phenotype might 
reflect a synthetic effect of more than one mutation (i.e. 
the ‘designed mutation’ plus extragenic transformation-
induced mutations that improve the fitness of the single 
mutant [73]). Finally, many important fungal characteris-
tics will be polygenic and their understanding will require 
experimental systems permitting those mutant versions 
of many genes are combinable with relative ease by mei-
otic recombination.
Future important technologies for filamentous 
fungi
Fungi are efficient enzyme producers but their rela-
tive inability to make heterologous proteins limits their 
usefulness. A key issue is that our understanding of the 
different pathways of exocytosis is very limited, and actu-
ally we do not even know how many ways a cargo has 
to reach the extracellular milieu. A major standing bot-
tleneck is the detailed understanding of these pathways 
and their regulatory circuitry to allow their tailored 
genetic manipulation. A better comprehension of intra-
cellular traffic may also ‘permeate’ to secondary metabo-
lite production. For example, the final steps of penicillin 
biosynthesis take place in the peroxisomes, such that 
these organelles have a profound influence on antibiotic 
titers [74]. Lastly, hyphal growth is strictly dependent 
on exocytosis, and thus essential fungal-specific aspects 
of intracellular traffic would be druggable for antifungal 
intervention. A key issue is that with the notable excep-
tion of the unfolded protein response [75], intracellular 
traffic is mainly regulated at post-transcriptional levels by 
small GTPases, lipids and their respective effectors [76]. 
Several technological developments will be helpful to 
gain further insight.
(i) In vivo imaging: Studies with fungal cells growing 
on the microscopy stage using movies with high 
time resolution. On the cell side these studies will 
require brighter fluorescent markers, ideally fully 
functional fluorescent fusion proteins expressed 
at physiological levels and, from the hardware 
side, equipment permitting 5-way multidimen-
sional acquisition (x, y, z, time, multiple channels) 
of images. These studies should be combined with 
acute inactivation of gene function ‘on-the-stage’, 
for example by exploiting available heat-sensitive 
mutations [77]. Besides suitable microscopy hard-
ware these studies will demand expert know-how 
on the techniques to image cells without perturb-
ing the process that is being observed. Moreo-
ver, improving the time resolution of time-lapse 
sequences implies progressively larger files that 
demand specialized software, dedicated high-
capacity digital storage resources and powerful 
computer workstations, a triple combination that 
will be only available in highly specialized central 
facilities. Lastly, the future of these microscopy 
studies undoubtedly passes through systems biol-
ogy, and our capacity to perform automated image 
analysis, to statistically interpret large amounts of 
data and to match them to mathematical models.
(ii) Biochemistry combined with shotgun proteomics: 
Intracellular compartments are transient entities, 
and thus difficult to define unless their composi-
tion is very precisely determined. We need bet-
ter subcellular fractionation procedures to obtain 
homogeneous populations of organelles and con-
necting carriers, possibly aided by appropriate 
genetic blocks. The composition of these organelle 
fractions needs to be elucidated by shotgun prot-
eomics and by lipidomics (a technology that is not 
generally available). Proteomics is often limited 
by the quality of the reference databases because 
genes/proteins are miss-predicted by automated 
gene call procedures. Improving the quality of 
peptide reference databases is essential to obtain-
ing more reliable proteomics data. This objective 
should be a major target of genome information 
repositories.
(iii) Electron microscopy: The subcellular organiza-
tion of filamentous fungi will not be understood 
without exploiting the recent developments in 
this field. Whenever used by technically compe-
tent laboratories tomography studies have yielded 
significant insights (see for example [78]). Further 
EM studies should undoubtedly involve the largely 
unexploited capabilities of immune-EM (for exam-
ple see [79]) and correlative EM-light microscopy 
[80].
(iv) Other technologies: Three further technologies were 
identified by the EUROFUNG group to be of crucial 
importance for basic and applied filamentous fungal 
research. On the one hand, single-cell analytics will 
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offer tremendous opportunities to study population 
heterogeneity at both the biological level (stochastic 
variations, molecular noise, regulatory effects) and 
environmental level (inhomogeneity, fluctuations 
and gradients in natural habitats and bioreactors). 
Microfluidic single-cell cultivation devices equipped 
with time lapse imaging for high-throughput omics 
analyses are available for academic groups study-
ing unicellular microorganisms [81] but not yet for 
filamentous fungal systems. There is thus a need 
for input from these research communities com-
bined to make these technologies widely applica-
ble for filamentous fungi [82]. Another technology 
frequently employed with unicellular microorgan-
isms but that is underdeveloped for filamentous 
fungi is flow cytometry. This technique in combi-
nation with cell sorting is very powerful for high-
throughput screenings, for example. Some prelimi-
nary approaches have already been published using 
large-particle flow cytometry [83, 84]; however, 
further developments are clearly necessary. A third 
potentially important technological development 
has been the application and refinement of single-
use bioreactors, such as wave-mixed bioreactors, 
for the medium-scale production of high-value 
products (up to 2.5  m3). These offer many oppor-
tunities for filamentous fungi as cell factories in 
pharmaceutical and cosmetics industries. Not only 
is this platform technology safer (decreased risk of 
microbial contamination and cross-contamination), 
greener (reduced requirements for cleaning and 
sterilization), faster and more flexible (easy process 
and product change), cheaper (saving of time and 
costs) and smaller (reduced facility footprint) [85], 
it offers better oxygen transfer rates, more homo-
geneous energy dissipation and comparable or bet-
ter growth of filamentous fungi when compared to 
their cultivation classical stirred tank reactors [85, 
86]. Of special interest for small-scale controlled 
solid state fungal (co-)cultivations (max. 25 L) are 
reusable gas–liquid-solid bioreactors based on the 
membrane gradostat bioreactor technology. They 
provide a low shear environment, do not need the 
addition of antifoam agents and give similar or bet-
ter results than in stirred reusable bioreactors as 
shown for A. niger, N. crassa and Penicillium spp. 
[87].
Which training programs are key for the 
next‑generation of fungal scientists?
There is a shortage of skilled researchers with multi-
disciplinary expertise in fungal molecular biology and 
biotechnology. The participants agreed that advanced 
research on fungal biology and biotechnology requires 
a multi-scale view—i.e. the combination of knowledge 
on cellular and molecular biology with mathematical 
modeling, statistical/computational tools and indus-
trial production—and hence a high level of expertise 
in these disciplines. Moreover, transfer of in silico and 
experimental skills between the complimentary areas of 
medical mycology, plant pathology, and industrial micro-
biology are severely limited. Hence, training of multidis-
ciplinary scientists with strong background in all fields 
will create an unparalleled environment for future devel-
opments such as antifungal drug discovery and new tech-
nological applications of filamentous fungi. In addition, 
industrial partners of EUROFUNG identified that there 
is a lack of staff within the biotechnology industry with 
expertise in fungal systems—consequently bacterial and 
yeast systems tend to be the default, when fungal systems 
may be the rational choice. This underlines the need for 
better training, particularly at the postgraduate levels and 
improved mechanism to promote knowledge transfer if 
we are to realise the potential that fungal biology offers.
There was firm agreement that ‘technician level bioin-
formaticians’ are needed. These are trained bioinforma-
ticians (e.g. to a bachelor or masters level) who are not 
actively involved in hypothesis generation, but fill an 
essential role by conducting bioinfomatic experiments 
and curating resources, rather than developing and test-
ing new software. This would increase lab bioinformatics 
capacity and enable the exploitation of growing in silico 
resources.
Finally, there is a barrier for knowledge exchange 
between industry and academia. Companies have 
become repositories of key knowledge and innovative 
technologies needed for education and research but the 
dissemination of this knowledge is limited due to the lack 
of coordinated training between the two sectors. Like-
wise, much academic research does not reach relevant 
industrial research and business development activities. 
Hence, future multidisciplinary training programs should 
involve cross-sectoral elements to enable the new genera-
tion of fungal scientists and biotechnologists to under-
stand the wider and economical potential of their work.
Conclusions
Significantly improved scientific understanding and bet-
ter translation of knowledge to underpin innovation is 
required to improve filamentous fungal based cell fac-
tories and to better control pathogenic fungi. Crucial 
for this are continuous efforts for high-quality anno-
tation and curation of fungal genomes, with continu-
ous financial support to make omics data and resources 
publicly available and comparable. Furthermore, a 
sophisticated synthetic biology tool box tailored to a 
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range of filamentous fungal species needs to be devel-
oped to overcome our limited flexibility to genetically 
modify and optimize them. Learning from work with 
well-chosen reference organisms, integrating systems-
level functional studies of pathogen and industrial 
organism biology will facilitate the development of new 
products, biosynthetic systems and new anti-fungal 
drug discovery programmes. The fungal biotechnology 
revolution is happening—the more young academics 
become trained and interested in multidisciplinary fun-
gal research the better! With their passion and enthusi-
asm the huge potential of filamentous fungal systems will 
be faster and better exploited, which will help society to 
address key challenges of the twenty-first century.
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